LIXTE Biotechnology Secures $16.57 Million in Direct Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: Newsfilter
- Significant Financing: LIXTE Biotechnology successfully completed a direct offering of approximately $16.57 million with accredited investors, priced at $6.31 per share, which materially strengthens the company's financial position and flexibility.
- Share Issuance Details: The transaction involved the sale of 2,625,362 shares of common stock and pre-funded warrants, with the warrants being immediately exercisable, expected to provide additional capital support for the company's strategic priorities.
- Support for Strategic Development: CEO Geordan Pursglove stated that this financing positions LIXTE with a stronger balance sheet for its next growth phase, enabling more effective execution of its strategic plans and creating long-term value for shareholders.
- New Board Member: Stuart D. Porter, founder of Denham Capital, has recently been appointed to the board, bringing over three decades of investment experience in energy and infrastructure, which will provide invaluable counsel for the company's strategic decision-making.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LIXT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LIXT
About LIXT
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LIXTE to Loan $6.5 Million to Support NOMAD Acquisition
- Loan for Order Support: LIXTE Biotechnology Holdings, Inc. will provide a $6.5 million loan to NOMAD prior to closing the acquisition, aimed at funding the procurement of long-lead components to ensure NOMAD can maintain production amidst accelerating customer demand.
- Corporate Renaming: Upon closing, LIXTE will be renamed NOMAD Power Solutions, Inc. and will trade under a new ticker symbol on Nasdaq, reflecting the company's focus on addressing power availability challenges in the utility and data center markets.
- Accelerated Market Demand: NOMAD's mobile battery energy storage systems have been utility-validated for real-time deployment in critical environments, meeting the unprecedented electricity demand driven by AI compute and high-density data infrastructure, highlighting its essential role in the modern grid.
- Strategic Investment Outlook: LIXTE CEO Geordan Pursglove stated that deploying capital ahead of closing reflects confidence in NOMAD's platform, aiming to accelerate commercialization by fulfilling the growing order backlog and ensuring a smooth transaction completion.
See More
LIXTE to Merge with NOMAD, Forming Power Solutions Company
- Strategic Transformation: LIXTE Biotechnology has entered into a merger agreement with NOMAD, transforming into a company focused on deployable power solutions, with the transaction expected to close on July 1, 2026, marking a significant shift in corporate strategy.
- Pre-Closing Investment: Prior to the deal's completion, LIXTE has loaned NOMAD $6.5 million to support the procurement of long-lead components and scale manufacturing, demonstrating management's strong confidence in market demand.
- Market Opportunity: NOMAD achieved approximately 175% year-over-year revenue growth in 2025, with projections of an additional 135% growth in 2026, and about 75% of its sales activities are driven by inbound customer inquiries, indicating robust demand in the rapidly expanding power market.
- Industry Challenges: As AI infrastructure expands rapidly, electricity demand is surging, outpacing the traditional grid's capacity; NOMAD's mobile power solutions are crucial in addressing this bottleneck, highlighting significant strategic implications for the market.
See More
LIXTE to Merge with NOMAD, Transforming into Power Solutions Company
- Strategic Transformation: LIXTE Biotechnology Holdings has entered into a merger agreement with NOMAD, planning to rename itself NOMAD Power Solutions, focusing on addressing the urgent power needs of AI infrastructure, with the transaction expected to close on July 1, 2026.
- Pre-Closing Investment: Before the deal closes, LIXTE has loaned $6.5 million to NOMAD to support the procurement of long-lead components and meet the growing order demand, demonstrating management's strong confidence in market needs.
- Market Opportunity: NOMAD achieved approximately 175% revenue growth in 2025, with an expected additional 135% growth in 2026, and about 75% of sales activities are initiated by customers, indicating its leading position in the rapidly expanding power market.
- Technological Advantage: NOMAD's mobile battery energy storage systems (BESS) can be deployed quickly to meet the immediate high-quality power demands of data centers, circumventing the time and approval bottlenecks associated with traditional power infrastructure construction.
See More
LIXTE Biotechnology to Merge with NOMAD, Transforming into Power Solutions Firm
- Company Repositioning: LIXTE Biotechnology has entered into a merger agreement with NOMAD, renaming itself NOMAD Power Solutions, Inc., which signifies a major strategic shift towards addressing the AI-driven power demand crisis.
- Pre-Closing Financial Support: LIXTE will provide NOMAD with a $6.5 million loan before the transaction closes to fund long-lead component procurement and working capital, ensuring customer demand is met ahead of the merger.
- Market Leadership: NOMAD is a market leader in deployable utility-grade battery energy storage systems, with projected revenue growth of approximately 175% in 2025 and an additional 135% in 2026, indicating strong market demand and growth potential.
- Addressing Power Bottlenecks: As AI infrastructure demand for electricity surges, NOMAD's deployable storage solutions provide fast and reliable power to data centers, filling the gap left by traditional grids, which holds significant strategic market implications.
See More
LIXTE to Merge with NOMAD, Transforming into Power Solutions Firm
- Company Repositioning: LIXTE Biotechnology Holdings has entered into a definitive agreement to merge with NOMAD, rebranding as NOMAD Power Solutions, Inc., focusing on addressing the power shortages of the AI era, with the transaction expected to close on July 1, 2026.
- Pre-Closing Financial Support: LIXTE will provide NOMAD with a $6.5 million loan before the deal closes to fund long-lead component procurement and working capital, demonstrating management's confidence in NOMAD's market potential.
- Market Leadership: NOMAD is a leader in deployable utility-grade battery energy storage systems, reporting approximately 175% revenue growth in 2025, with an additional projected growth of 135% in 2026, indicating strong market demand and customer interest.
- Addressing Power Bottlenecks: As AI infrastructure drives surging electricity demand, NOMAD's deployable storage solutions offer rapid and reliable power supply to data centers, effectively filling the gaps that traditional grids cannot meet.
See More
LIXTE Acquires NOMAD to Address Power Shortages
- Power Supply Challenge: Approximately 2.3 terawatts of generation and storage capacity are currently in U.S. interconnection queues, with the time to develop new capacity extending from two years to five to seven years, highlighting the urgency and investment opportunity in power supply.
- Strategic Acquisition: LIXTE Biotechnology Holdings has announced the acquisition of NOMAD Transportable Power Systems, intending to rename itself NOMAD Power Solutions, which emphasizes its commitment to the power availability market and innovative solutions.
- Market Growth Potential: NOMAD's mobile battery systems can bypass the complex approval processes of traditional power projects, which is expected to drive rapid growth in the North American market, with management projecting a revenue increase of approximately 175% year-over-year in 2025.
- Competitive Advantage: NOMAD's transportable systems provide a significant competitive edge in regions where battery storage projects face restrictions, enabling quick deployment to meet urgent customer power needs, positioning the company as a key player in emerging power infrastructure.
See More
LIXTE to Loan $6.5 Million to Support NOMAD Acquisition
- Loan for Order Support: LIXTE Biotechnology Holdings, Inc. will provide a $6.5 million loan to NOMAD prior to closing the acquisition, aimed at funding the procurement of long-lead components to ensure NOMAD can maintain production amidst accelerating customer demand.
- Corporate Renaming: Upon closing, LIXTE will be renamed NOMAD Power Solutions, Inc. and will trade under a new ticker symbol on Nasdaq, reflecting the company's focus on addressing power availability challenges in the utility and data center markets.
- Accelerated Market Demand: NOMAD's mobile battery energy storage systems have been utility-validated for real-time deployment in critical environments, meeting the unprecedented electricity demand driven by AI compute and high-density data infrastructure, highlighting its essential role in the modern grid.
- Strategic Investment Outlook: LIXTE CEO Geordan Pursglove stated that deploying capital ahead of closing reflects confidence in NOMAD's platform, aiming to accelerate commercialization by fulfilling the growing order backlog and ensuring a smooth transaction completion.
See More
LIXTE to Merge with NOMAD, Forming Power Solutions Company
- Strategic Transformation: LIXTE Biotechnology has entered into a merger agreement with NOMAD, transforming into a company focused on deployable power solutions, with the transaction expected to close on July 1, 2026, marking a significant shift in corporate strategy.
- Pre-Closing Investment: Prior to the deal's completion, LIXTE has loaned NOMAD $6.5 million to support the procurement of long-lead components and scale manufacturing, demonstrating management's strong confidence in market demand.
- Market Opportunity: NOMAD achieved approximately 175% year-over-year revenue growth in 2025, with projections of an additional 135% growth in 2026, and about 75% of its sales activities are driven by inbound customer inquiries, indicating robust demand in the rapidly expanding power market.
- Industry Challenges: As AI infrastructure expands rapidly, electricity demand is surging, outpacing the traditional grid's capacity; NOMAD's mobile power solutions are crucial in addressing this bottleneck, highlighting significant strategic implications for the market.
See More
LIXTE to Merge with NOMAD, Transforming into Power Solutions Company
- Strategic Transformation: LIXTE Biotechnology Holdings has entered into a merger agreement with NOMAD, planning to rename itself NOMAD Power Solutions, focusing on addressing the urgent power needs of AI infrastructure, with the transaction expected to close on July 1, 2026.
- Pre-Closing Investment: Before the deal closes, LIXTE has loaned $6.5 million to NOMAD to support the procurement of long-lead components and meet the growing order demand, demonstrating management's strong confidence in market needs.
- Market Opportunity: NOMAD achieved approximately 175% revenue growth in 2025, with an expected additional 135% growth in 2026, and about 75% of sales activities are initiated by customers, indicating its leading position in the rapidly expanding power market.
- Technological Advantage: NOMAD's mobile battery energy storage systems (BESS) can be deployed quickly to meet the immediate high-quality power demands of data centers, circumventing the time and approval bottlenecks associated with traditional power infrastructure construction.
See More
LIXTE Biotechnology to Merge with NOMAD, Transforming into Power Solutions Firm
- Company Repositioning: LIXTE Biotechnology has entered into a merger agreement with NOMAD, renaming itself NOMAD Power Solutions, Inc., which signifies a major strategic shift towards addressing the AI-driven power demand crisis.
- Pre-Closing Financial Support: LIXTE will provide NOMAD with a $6.5 million loan before the transaction closes to fund long-lead component procurement and working capital, ensuring customer demand is met ahead of the merger.
- Market Leadership: NOMAD is a market leader in deployable utility-grade battery energy storage systems, with projected revenue growth of approximately 175% in 2025 and an additional 135% in 2026, indicating strong market demand and growth potential.
- Addressing Power Bottlenecks: As AI infrastructure demand for electricity surges, NOMAD's deployable storage solutions provide fast and reliable power to data centers, filling the gap left by traditional grids, which holds significant strategic market implications.
See More
LIXTE to Merge with NOMAD, Transforming into Power Solutions Firm
- Company Repositioning: LIXTE Biotechnology Holdings has entered into a definitive agreement to merge with NOMAD, rebranding as NOMAD Power Solutions, Inc., focusing on addressing the power shortages of the AI era, with the transaction expected to close on July 1, 2026.
- Pre-Closing Financial Support: LIXTE will provide NOMAD with a $6.5 million loan before the deal closes to fund long-lead component procurement and working capital, demonstrating management's confidence in NOMAD's market potential.
- Market Leadership: NOMAD is a leader in deployable utility-grade battery energy storage systems, reporting approximately 175% revenue growth in 2025, with an additional projected growth of 135% in 2026, indicating strong market demand and customer interest.
- Addressing Power Bottlenecks: As AI infrastructure drives surging electricity demand, NOMAD's deployable storage solutions offer rapid and reliable power supply to data centers, effectively filling the gaps that traditional grids cannot meet.
See More
LIXTE Acquires NOMAD to Address Power Shortages
- Power Supply Challenge: Approximately 2.3 terawatts of generation and storage capacity are currently in U.S. interconnection queues, with the time to develop new capacity extending from two years to five to seven years, highlighting the urgency and investment opportunity in power supply.
- Strategic Acquisition: LIXTE Biotechnology Holdings has announced the acquisition of NOMAD Transportable Power Systems, intending to rename itself NOMAD Power Solutions, which emphasizes its commitment to the power availability market and innovative solutions.
- Market Growth Potential: NOMAD's mobile battery systems can bypass the complex approval processes of traditional power projects, which is expected to drive rapid growth in the North American market, with management projecting a revenue increase of approximately 175% year-over-year in 2025.
- Competitive Advantage: NOMAD's transportable systems provide a significant competitive edge in regions where battery storage projects face restrictions, enabling quick deployment to meet urgent customer power needs, positioning the company as a key player in emerging power infrastructure.
See More
